Samsung Biologics
| Company type | Public |
|---|---|
| KRX: 207940 | |
| Industry | Biopharmaceuticals |
| Founded | 2011 |
| Headquarters | , South Korea |
Area served | Worldwide |
Key people | John Rim (president and CEO) |
| Revenue | KRW 4.55 trillion (2024) |
| KRW 325.7 billion (2024) | |
| Owners |
|
Number of employees | 4,300 (2023) |
| Subsidiaries | Samsung Bioepis |
| Korean name | |
| Hangul | 삼성바이오로직스 |
| Revised Romanization | Samseong Baiorojikseu |
| McCune–Reischauer | Samsŏng Paiorojiksŭ |
| Website | samsungbiologics |
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb.